LAST WEEK TODAY!

A summary of what was published on ProstateWarriors.com during the past week

Hi fellow warriors! This time, I welcome you with the Milky Way!

This week, we have some exciting updates on cutting-edge treatments in clinical and preclinical trials. I hope you find them as fascinating as I do! I bet you can guess which one impressed me the most!

As usual, we also have a podcast if you prefer to listen to the newsletter, you can find it HERE.​

Clinical Research

• 67Cu-SAR-bisPSMA for mCRPC​
  The FDA has granted Fast Track Designation to expedite development. In a Phase 1/2a trial, 73% of participants showed reduced PSA levels, with 45% achieving reductions greater than 50%. One heavily pre-treated patient experienced a complete response after just two doses, maintaining undetectable PSA levels for 13 months,Âaccording to the latest follow-up data. The SECuRE trial is also assessing its integration with enzalutamide.
  ​
• Lu-PSMA vs Cabazitaxel​
  Demonstrated superior efficacy compared to cabazitaxel chemotherapy in mCRPC patients. Clinical data shows that 32% of Lu-PSMA patients achieved a 50% or greater PSA reduction, whereas none in the cabazitaxel group did. The median progression-free survival was 13.4 months versus 7.1 months for cabazitaxel. Overall survival was 16.5 versus 14.7 months for cabazitaxel, but patients receiving both treatments had a median OS of 29.6 months.​
  ​
• Cabozantinib and Atezolizumab CombinationÂ​
  A study showed promising results, with 25.8% of patients in the combination therapy group remaining progression-free at 12 months, compared to 14.0% in the monotherapy group. For patients with liver metastases, median survival improved to 14.7 months, compared to 5.0 months with monotherapy.
  ​
• ENV105 to Reverse ADT/ARSI Resistance​
  Under investigation for restoring treatment sensitivity in castrate-resistant prostate cancer (CRPC). A Phase 2 trial is evaluating its combination with apalutamide, with earlier studies indicating a 62% clinical benefit rate among CRPC patients with limited treatment options. This could be a game changer for us while we wait for some cure (see below!)

Preclinical Research

• New Compound for Bone Metastasis
  ​A gallium and bioactive glass-based injectable paste has shown a 99% success rate in eliminating bone cancer cells while promoting new bone growth in lab settings. This targeted approach delivers anticancer gallium ions directly to tumor sites, reducing recurrence and enhancing bone healing.​
  ​
• AI-Driven Drug Repurposing​
  Predictive Oncology Inc.’s AI platform has analyzed around 1,000 drug-tumor interactions, identifying potential treatments for ovarian, colon, and breast cancers. In early tests, two repurposed drugs outperformed a standard colon cancer treatment, highlighting AI’s role in streamlining drug development.
  ​
• EVO 2 AI for Genetic Engineering – POTENTIALLY GROUNDBREAKING​
  Trained on over 128,000 genomes and 9.3 trillion nucleotides, it can analyze sequences up to one million nucleotides long and propose new CRISPR variants. With over 90% accuracy in identifying pathogenic BRCA1 mutations, it is capable of generating entire bacterial-scale genomes, including tRNA and rRNA genes. Evo 2 AI is open-source and integrated with NVIDIA’s BioNeMo framework, offering a transformative tool for medicine, agriculture, and biotechnology. This tool has the potential to redefine genome design and mutation prediction.
  ​

And…that’s all folks! For today at least!
Please let me know if there is anything I can improve in my newsletters, and let me know if you have enjoyed the podcast.

If you this newsletter was delivered to your SPAM folder, make sure to let your email system know that it is not spam.
​
​
Have a great weekend!

Max